Zepbound vs. Wegovy (2026): Price, Results, Indications — the Complete Head-to-Head

The two flagship obesity injections are no longer separated by availability, coverage exotica, or four-figure list prices — in 2026 they compete on the merits, and the merits split cleanly. Zepbound (tirzepatide) wins on weight loss, decisively and head-to-head. Wegovy (semaglutide) wins on cardiovascular evidence, price structure, starter economics, and format options. Here is the complete comparison, every number current to August 2026.

Efficacy: the head-to-head answer

This is the rare drug comparison with a direct randomized answer. SURMOUNT-5 put maximum-tolerated tirzepatide against semaglutide 2.4 mg in 751 adults for 72 weeks: 20.2% average body-weight loss versus 13.7% — roughly fifty pounds versus thirty-three — with more tirzepatide patients clearing every threshold (15%, 20%, 25%). The mechanism explains it: tirzepatide adds GIP-receptor agonism to the GLP-1 activity both drugs share, and the second incretin buys the gap. If maximum weight loss is the sole criterion, the comparison ends here, and it ends for Zepbound. It is not the sole criterion.

Indications: two different second acts

Beyond obesity, the labels diverge in ways that decide real coverage outcomes. Wegovy carries the class's crown jewel: a cardiovascular risk-reduction indication, earned by the SELECT trial's 20% cut in major cardiovascular events across 17,604 patients with established heart disease and overweight — without diabetes. For a patient with a cardiac history, that indication opens insurance doors that "weight loss" exclusions keep shut, including Medicare pathways. Zepbound answered with obstructive sleep apnea: the SURMOUNT-OSA program showed AHI reductions around 60%, the FDA approved the indication in December 2024, and a documented OSA diagnosis now routes around weight-loss exclusions the same way — the mechanics are in our Zepbound-for-sleep-apnea guide. Neither label covers the other's territory yet (tirzepatide's SURPASS-CVOT cardiovascular win was in diabetes, against an active comparator), so for many insured patients, the diagnosis you carry picks the drug before preference does.

Price: structure beats sticker

The self-pay structures are philosophically different. Zepbound prices by dose through LillyDirect: $299 (2.5 mg starter), $399 (5 mg), $449 (7.5–15 mg) — identical at retail KwikPens (Walmart included, since March 2026) and roughly $350 on TrumpRx — with a ~45-day refill cadence requirement whose lapse reprices fills at $599–$1,049 until re-enrollment. Wegovy charges a flat $349 at every standard dose ($399 for the 7.2 mg high dose), with $199 for each of the first two starter fills and no cadence trap. Run the ladders honestly: Zepbound's first titrated year costs about $5,188; Wegovy's costs $3,888–$4,188 depending on the starter offer — and at maintenance the gap settles at $100 a month, $1,200 a year, in Wegovy's favor. Both drop to $25 copays with commercial coverage plus savings cards, and both sit in Medicare's new ~$50 tier for qualifying patients, where the price question dissolves entirely.

Everything else that decides it

Formats: Wegovy offers pens and an oral tablet (launched at $149 intro; strict empty-stomach rules); Zepbound offers pens and cheaper single-dose vials but no pill — no oral tirzepatide exists. Side effects: class-identical in kind (GI-dominant, titration-clustered), with SURMOUNT-5 showing comparable tolerability despite tirzepatide's greater efficacy; both carry the boxed warning and the same contraindications. Supply: both are post-shortage and reliably stocked in 2026. The compounded shadow market: both molecules exist in compounded form at lower prices (tirzepatide from $215, semaglutide from $133) — not FDA-approved, separately analyzed, and irrelevant to this brand-vs-brand question except as the outside option both prices must beat.

The verdict, by buyer

Pick Zepbound if maximum weight loss is the goal and the budget clears $449 at maintenance (or your OSA diagnosis opens coverage); the head-to-head gap of 6.5 percentage points — roughly 17 extra pounds for the average patient — is the largest efficacy difference money can currently buy at a pharmacy. Pick Wegovy if you carry cardiovascular disease (the indication is decisive), if the flat $349 and $199 starter economics matter, if you want the pill escape hatch, or if you're optimizing durability of adherence over peak effect. Either way, run the coverage check first — at $25–$50, the comparison inverts from "which is cheaper" to "which does my plan prefer" — via the insurance guide. And if neither self-pay number fits, that is the question the rest of this site's rankings exist to price.

The first-year ledgers, month by month

Annualizing hides the shape of spending, so walk both first years at self-pay. Zepbound: $299 (month one, 2.5 mg) + $399 (month two, 5 mg) + $449 × 10 (months three through twelve, assuming the standard climb through 7.5 mg to a 10 mg hold) = $5,188, with the 45-day cadence as the tripwire — one lapsed refill and subsequent fills reprice at $599–$1,049 until re-enrollment, a fine print that has cost inattentive patients four figures. Wegovy: $199 + $199 (starter offer, months one and two) + $349 × 10 = $3,888, no cadence trap, flat forever after — or $4,188 without the starter offer. The gap — $1,000–$1,300 in year one, $1,200 every maintenance year after — is the recurring price of SURMOUNT-5's 6.5 extra percentage points, which for a 220-pound starter is roughly 14 additional pounds. Whether a pound is worth $85–$90 a year is a genuinely personal equation; what's not personal is knowing you're solving it.

Tolerability and logistics, close-read

SURMOUNT-5's secondary story mattered as much as its headline: tirzepatide delivered its extra efficacy at comparable tolerability — GI adverse-event rates and discontinuations in the same band as semaglutide's, dissolving the old assumption that more effect must cost more misery (mechanistically credited to GIP's possible anti-nausea contribution). The remaining practical differences are logistical. Zepbound's single-dose vials (the $299–$449 program's cheapest format) mean syringe draws and cold-box deliveries; its KwikPens now sit at retail everywhere. Wegovy is pens throughout, plus the tablet escape hatch. Both are weekly, same-day-each-week, with identical missed-dose windows; both titrate on four-week rungs with dose-holds as the standard side-effect play. Travel, needle comfort, and pharmacy preference decide more real-world satisfaction here than any trial endpoint — and none of it should decide before the coverage check that can make the whole price section moot.

The switching traffic, both directions

Real-world flows between these two say as much as the trials. The dominant direction is Wegovy→Zepbound after plateaus — the standard upgrade, typically entering tirzepatide at 5 mg rather than the ceremonial 2.5 — driven by the head-to-head gap. The reverse flow is smaller but real: Zepbound→Wegovy for cardiovascular-indication coverage, for the $100/month maintenance saving once goals are met, or for the tablet option when needles stop being tolerable. Both moves are same-class transitions without washouts; both reset the titration conversation, not the treatment; and both are cheaper to execute than a year of paying for the wrong fit. The only expensive version is the unplanned one — lapsing Zepbound's 45-day cadence mid-decision and meeting the $599–$1,049 repricing while you deliberate.

Three buyers, priced through both doors

Abstractions decide nothing, so run the actual arithmetic on three common situations. The uncovered cash payer chasing maximum loss: Zepbound's first titrated year costs ~$5,188 and each maintenance year $5,388; Wegovy's runs ~$3,888–$4,188 then $4,188 — so the head-to-head's extra ~6.5 percentage points cost roughly $1,200 a year, or about $185 per additional expected percentage point. Framed that way, plenty of budgets pick Zepbound anyway, and the compounded tirzepatide route at $215 exists precisely for the ones that can't. The covered patient with cardiac history: SELECT's indication makes Wegovy the path of least prior-auth resistance and often the only covered path — a $25 copay for the on-label drug beats a denied appeal for the stronger one, and the efficacy gap matters less than the adherence a covered price buys. The OSA patient who hates the CPAP: Zepbound's sleep-apnea label flips the coverage logic the other way — the sleep study becomes the key, the OSA pathway the door, and Wegovy isn't on that label at all. The meta-lesson across all three: in 2026, indication fit and coverage status pick the brand more often than the head-to-head does — the trial data breaks ties, not budgets.

The questions that don't decide it

Worth naming what shouldn't drive this choice, because marketing works the margins. Injection experience: both are weekly autoinjector pens of near-identical friction — needle-phobia distinguishes pill-versus-injection, not these two. Side-effect reputation: the profiles are class-identical in kind and, per the head-to-head, comparable in burden; individual variation swamps brand differences, and switching exists for the unlucky. Celebrity molecule associations: "the Ozempic one" versus "the new one" is search-volume trivia, not pharmacology. And month-one price: the $199-versus-$299 starter skirmish is a rounding error against the $1,200-a-year maintenance gap and the five-figure multi-year picture — the annual-cost view is the honest lens. What's left after clearing the noise is the real decision set this article priced: efficacy ceiling, indication fit, coverage status, and maintenance budget. Four inputs, one afternoon of paperwork-checking, and the answer usually writes itself. And if it doesn't — if you're genuinely torn between $1,200 of annual savings and 6.5 percentage points of expected result — that tie itself is information: it means either drug will serve, the switch path stays open in both directions, and the rational move is starting with whichever one your coverage, pharmacy, and calendar make frictionless this month.